Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-07-28
Recursion Pharmaceuticals, Inc.
Recursion develops investigational medicines and drug-discovery collaborations using its AI-enabled Recursion OS platform, automated labs, and in-house compute.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof-Driven Rerating With Real but Gated Upside
The opportunity is a proof-driven rerating: show that the closed-loop data-and-lab system repeatedly creates human-validated assets, and value capture can migrate upward fast. Fail to prove repeatability, and the business stays a cash-burning discovery contractor with lumpy economics.

Analysis

Thesis
Recursion is a cash-backed option on proving that proprietary data, automated labs, and compute can repeatedly create clinically useful assets; if REC-4881 secures a credible registrational path and at least one more owned program validates in humans, value capture can move from lumpy discovery services toward richer milestone, royalty, and owned-asset economics by 2031.
Last Economy Alignment
Cheaper cognition helps Recursion because its moat is not a thin software wrapper; it owns the data, lab loop, and contract surfaces. The cap on the score is that FDA and human outcomes, not model quality alone, determine value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
This is mainly a rerating plus execution case. The stock does not need a heroic blockbuster forecast; it needs one credible late-stage path, a second human proof point, and collaboration structures that keep more downstream economics. If those pieces land, investors can value the business less like a cash-burning discovery contractor and more like a repeatable drug-creation engine.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is not whether Recursion can run AI-driven discovery; it is whether that engine can produce repeated human clinical proof before cash burn weakens bargaining power or forces dilution. REC-4881 regulatory clarity is the dominant gate, a second owned-program proof point is the next one, and both matter more than incremental software progress.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.54
They control hard-to-copy lab data, compute, and experimental workflows, so cheaper AI makes their engine more useful instead of replacing it. The catch is that FDA and human trial results, not model quality alone, decide whether that advantage turns into durable money.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.25
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case